CN112334465A - 三环取代的氧杂螺环衍生物、其制法与医药上的用途 - Google Patents

三环取代的氧杂螺环衍生物、其制法与医药上的用途 Download PDF

Info

Publication number
CN112334465A
CN112334465A CN202080003464.1A CN202080003464A CN112334465A CN 112334465 A CN112334465 A CN 112334465A CN 202080003464 A CN202080003464 A CN 202080003464A CN 112334465 A CN112334465 A CN 112334465A
Authority
CN
China
Prior art keywords
alkyl
substituted
unsubstituted
compound
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080003464.1A
Other languages
English (en)
Inventor
胡斌
刘力锋
石晓永
杨文�
关慧平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Original Assignee
Yangtze River Pharmaceutical Group Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yangtze River Pharmaceutical Group Co Ltd, Shanghai Haiyan Pharmaceutical Technology Co Ltd filed Critical Yangtze River Pharmaceutical Group Co Ltd
Publication of CN112334465A publication Critical patent/CN112334465A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供了三环取代的氧杂螺环衍生物、其制法与医药上的用途。具体地，公开了式(I)和式(Ⅱ)化合物或其药学上可接受的盐、立体异构体或溶剂化物，及其制备方法和应用。

Description

PCT国内申请，说明书已公开。

Claims (28)

  1. PCT国内申请，权利要求书已公开。
CN202080003464.1A 2019-01-17 2020-01-17 三环取代的氧杂螺环衍生物、其制法与医药上的用途 Pending CN112334465A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100443731 2019-01-17
CN201910044373 2019-01-17
PCT/CN2020/072851 WO2020147848A1 (zh) 2019-01-17 2020-01-17 三环取代的氧杂螺环衍生物、其制法与医药上的用途

Publications (1)

Publication Number Publication Date
CN112334465A true CN112334465A (zh) 2021-02-05

Family

ID=71614130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080003464.1A Pending CN112334465A (zh) 2019-01-17 2020-01-17 三环取代的氧杂螺环衍生物、其制法与医药上的用途

Country Status (2)

Country Link
CN (1) CN112334465A (zh)
WO (1) WO2020147848A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129495A1 (en) * 2011-03-23 2012-09-27 Trevena, Inc. Opioid receptor ligands and methods of using and making same
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用
WO2017106306A1 (en) * 2015-12-14 2017-06-22 Trevena, Inc. Methods of treating hyperalgesia
WO2018188641A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种mor激动剂与kor激动剂的药物组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020005660A (es) * 2017-12-06 2020-08-20 Jiangsu Hengrui Medicine Ltd Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor.
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129495A1 (en) * 2011-03-23 2012-09-27 Trevena, Inc. Opioid receptor ligands and methods of using and making same
WO2017063509A1 (zh) * 2015-10-15 2017-04-20 江苏恒瑞医药股份有限公司 氧杂螺环类衍生物、其制备方法及其在医药上的应用
WO2017106306A1 (en) * 2015-12-14 2017-06-22 Trevena, Inc. Methods of treating hyperalgesia
WO2018188641A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种mor激动剂与kor激动剂的药物组合物及其用途

Also Published As

Publication number Publication date
WO2020147848A1 (zh) 2020-07-23

Similar Documents

Publication Publication Date Title
CN108430998B (zh) 氮杂双环衍生物及其制备方法和用途
CN101511796B (zh) 咪唑衍生物
AU2016215432B2 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
CN107001278B (zh) 四氢异喹啉衍生物
WO2018086591A1 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN111662284B (zh) 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111217802B (zh) 一类组蛋白乙酰化酶p300抑制剂及其用途
TW202216686A (zh) 藉由使ｅｇｆｒ抑制劑與ｅ３連接酶配位體結合來降解（ｅｇｆｒ）以及使用方法
JP7442652B2 (ja) アザビシクロ置換オキサスピロ環誘導体、その調製方法及び医学的使用
WO2020103884A1 (en) Cyclic Ureas
TW201111356A (en) Nitrogen-containing compound and pharmaceutical composition
CN110494433A (zh) 布鲁顿酪氨酸激酶抑制剂
WO2021143803A1 (zh) 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
JP2011509302A (ja) キナーゼ阻害薬としてのピラゾロピリジン
CN114591293A (zh) 作为Nav1.8抑制剂的并环化合物及其用途
WO2022194269A1 (zh) 新型egfr降解剂
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
KR20230107802A (ko) Hsd17b13 억제제 및 이의 용도
WO2018086592A1 (zh) 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途
WO2021027304A1 (zh) 镇痛化合物、其制法与医药上的用途
CN112334465A (zh) 三环取代的氧杂螺环衍生物、其制法与医药上的用途
JP2024509243A (ja) 複素環置換ケトン類誘導体、その組成物および医薬における使用
CN113754635A (zh) 稠环类化合物及其制备方法和用途
CN114085220A (zh) 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
WO2019242599A1 (zh) 四氢异喹啉类衍生物、其制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination